Dogwood Therapeutics Admits First 200 Participants In Its Current HAL-CINP Phase 2b Study To Evaluate Efficacy, Safety Of Halneuron
Dogwood Therapeutics Inc DWTX
$1.64
▲ +3.80%
(+$0.06)
⬆️ Above Yest. High
🎈 Low Float
🗓️ Earnings Next Week
Open
$1.54
Prev Close
$1.58
Day Range
$1.50 – $1.64
52W Range
$1.28 – $9.50
Market Cap
$55.15M
Beta
1.78
EPS (TTM)
$-10.60
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-12-17 |
| Shares Out. | 33,630,000 |
| Website | dwtx.com/ ↗ |
| Phone | 18666208655 |
| Employees | 8 |
| Net Income | -$5.0M |
| Total Assets | $95.2M |
| Total Liabilities | $14.6M |
| Equity | $80.6M |
About Dogwood Therapeutics Inc
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
Dogwood Therapeutics Inc is a publicly traded company under the ticker symbol DWTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)